Home Healthcare Pharmaceuticals Retinal Vein Occlusion Market

Retinal Vein Occlusion Market Size, Share & Trends Analysis Report By Disease Type (Central Retinal Vein Occlusion (CRVO), Branch Retinal Vein Occlusion (BRVO)), By Treatment (Anti-vascular Endothelial Growth Factor (Anti-VEGF), Corticosteroid Drugs, Other Treatments), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, Other End Users) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: July 30, 2026 | Author: Debashree B | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Retinal Vein Occlusion Market, By Disease Type 2022-2034 (USD MILLION/ Units)
    1. Central Retinal Vein Occlusion (CRVO)
    2. Branch Retinal Vein Occlusion (BRVO)
  2. Retinal Vein Occlusion Market, By Treatment 2022-2034 (USD MILLION/ Units)
    1. Anti-vascular Endothelial Growth Factor (Anti-VEGF)
    2. Corticosteroid Drugs
    3. Other Treatments
  3. Retinal Vein Occlusion Market, By Distribution Channel 2022-2034 (USD MILLION/ Units)
    1. Hospital Pharmacies
    2. Drug Stores & Retail Pharmacies
    3. Other End Users
  4. Regional Retinal Vein Occlusion Market
    1. North America
      1. North America Retinal Vein Occlusion Market By Disease Type 2022-2034 (USD MILLION/ Units)
        1. Central Retinal Vein Occlusion (CRVO)
        2. Branch Retinal Vein Occlusion (BRVO)
      2. North America Retinal Vein Occlusion Market By Treatment 2022-2034 (USD MILLION/ Units)
        1. Anti-vascular Endothelial Growth Factor (Anti-VEGF)
        2. Corticosteroid Drugs
        3. Other Treatments
      3. North America Retinal Vein Occlusion Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Other End Users
      4. U.S.
        1. Central Retinal Vein Occlusion (CRVO)
        2. Branch Retinal Vein Occlusion (BRVO)
        3. Anti-vascular Endothelial Growth Factor (Anti-VEGF)
        4. Corticosteroid Drugs
        5. Other Treatments
        6. Hospital Pharmacies
        7. Drug Stores & Retail Pharmacies
        8. Other End Users
      5. Canada
        1. Central Retinal Vein Occlusion (CRVO)
        2. Branch Retinal Vein Occlusion (BRVO)
        3. Anti-vascular Endothelial Growth Factor (Anti-VEGF)
        4. Corticosteroid Drugs
        5. Other Treatments
        6. Hospital Pharmacies
        7. Drug Stores & Retail Pharmacies
        8. Other End Users
    2. Europe
      1. Europe Retinal Vein Occlusion Market By Disease Type 2022-2034 (USD MILLION/ Units)
        1. Central Retinal Vein Occlusion (CRVO)
        2. Branch Retinal Vein Occlusion (BRVO)
      2. Europe Retinal Vein Occlusion Market By Treatment 2022-2034 (USD MILLION/ Units)
        1. Anti-vascular Endothelial Growth Factor (Anti-VEGF)
        2. Corticosteroid Drugs
        3. Other Treatments
      3. Europe Retinal Vein Occlusion Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Other End Users
      4. U.K.
        1. Central Retinal Vein Occlusion (CRVO)
        2. Branch Retinal Vein Occlusion (BRVO)
        3. Anti-vascular Endothelial Growth Factor (Anti-VEGF)
        4. Corticosteroid Drugs
        5. Other Treatments
        6. Hospital Pharmacies
        7. Drug Stores & Retail Pharmacies
        8. Other End Users
      5. Germany
        1. Central Retinal Vein Occlusion (CRVO)
        2. Branch Retinal Vein Occlusion (BRVO)
        3. Anti-vascular Endothelial Growth Factor (Anti-VEGF)
        4. Corticosteroid Drugs
        5. Other Treatments
        6. Hospital Pharmacies
        7. Drug Stores & Retail Pharmacies
        8. Other End Users
      6. France
        1. Central Retinal Vein Occlusion (CRVO)
        2. Branch Retinal Vein Occlusion (BRVO)
        3. Anti-vascular Endothelial Growth Factor (Anti-VEGF)
        4. Corticosteroid Drugs
        5. Other Treatments
        6. Hospital Pharmacies
        7. Drug Stores & Retail Pharmacies
        8. Other End Users
      7. Spain
        1. Central Retinal Vein Occlusion (CRVO)
        2. Branch Retinal Vein Occlusion (BRVO)
        3. Anti-vascular Endothelial Growth Factor (Anti-VEGF)
        4. Corticosteroid Drugs
        5. Other Treatments
        6. Hospital Pharmacies
        7. Drug Stores & Retail Pharmacies
        8. Other End Users
      8. Italy
        1. Central Retinal Vein Occlusion (CRVO)
        2. Branch Retinal Vein Occlusion (BRVO)
        3. Anti-vascular Endothelial Growth Factor (Anti-VEGF)
        4. Corticosteroid Drugs
        5. Other Treatments
        6. Hospital Pharmacies
        7. Drug Stores & Retail Pharmacies
        8. Other End Users
      9. Russia
        1. Central Retinal Vein Occlusion (CRVO)
        2. Branch Retinal Vein Occlusion (BRVO)
        3. Anti-vascular Endothelial Growth Factor (Anti-VEGF)
        4. Corticosteroid Drugs
        5. Other Treatments
        6. Hospital Pharmacies
        7. Drug Stores & Retail Pharmacies
        8. Other End Users
      10. Nordic
        1. Central Retinal Vein Occlusion (CRVO)
        2. Branch Retinal Vein Occlusion (BRVO)
        3. Anti-vascular Endothelial Growth Factor (Anti-VEGF)
        4. Corticosteroid Drugs
        5. Other Treatments
        6. Hospital Pharmacies
        7. Drug Stores & Retail Pharmacies
        8. Other End Users
      11. Benelux
        1. Central Retinal Vein Occlusion (CRVO)
        2. Branch Retinal Vein Occlusion (BRVO)
        3. Anti-vascular Endothelial Growth Factor (Anti-VEGF)
        4. Corticosteroid Drugs
        5. Other Treatments
        6. Hospital Pharmacies
        7. Drug Stores & Retail Pharmacies
        8. Other End Users
      12. Rest of Europe
        1. Central Retinal Vein Occlusion (CRVO)
        2. Branch Retinal Vein Occlusion (BRVO)
        3. Anti-vascular Endothelial Growth Factor (Anti-VEGF)
        4. Corticosteroid Drugs
        5. Other Treatments
        6. Hospital Pharmacies
        7. Drug Stores & Retail Pharmacies
        8. Other End Users
    3. APAC
      1. APAC Retinal Vein Occlusion Market By Disease Type 2022-2034 (USD MILLION/ Units)
        1. Central Retinal Vein Occlusion (CRVO)
        2. Branch Retinal Vein Occlusion (BRVO)
      2. APAC Retinal Vein Occlusion Market By Treatment 2022-2034 (USD MILLION/ Units)
        1. Anti-vascular Endothelial Growth Factor (Anti-VEGF)
        2. Corticosteroid Drugs
        3. Other Treatments
      3. APAC Retinal Vein Occlusion Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Other End Users
      4. China
        1. Central Retinal Vein Occlusion (CRVO)
        2. Branch Retinal Vein Occlusion (BRVO)
        3. Anti-vascular Endothelial Growth Factor (Anti-VEGF)
        4. Corticosteroid Drugs
        5. Other Treatments
        6. Hospital Pharmacies
        7. Drug Stores & Retail Pharmacies
        8. Other End Users
      5. Korea
        1. Central Retinal Vein Occlusion (CRVO)
        2. Branch Retinal Vein Occlusion (BRVO)
        3. Anti-vascular Endothelial Growth Factor (Anti-VEGF)
        4. Corticosteroid Drugs
        5. Other Treatments
        6. Hospital Pharmacies
        7. Drug Stores & Retail Pharmacies
        8. Other End Users
      6. Japan
        1. Central Retinal Vein Occlusion (CRVO)
        2. Branch Retinal Vein Occlusion (BRVO)
        3. Anti-vascular Endothelial Growth Factor (Anti-VEGF)
        4. Corticosteroid Drugs
        5. Other Treatments
        6. Hospital Pharmacies
        7. Drug Stores & Retail Pharmacies
        8. Other End Users
      7. India
        1. Central Retinal Vein Occlusion (CRVO)
        2. Branch Retinal Vein Occlusion (BRVO)
        3. Anti-vascular Endothelial Growth Factor (Anti-VEGF)
        4. Corticosteroid Drugs
        5. Other Treatments
        6. Hospital Pharmacies
        7. Drug Stores & Retail Pharmacies
        8. Other End Users
      8. Australia
        1. Central Retinal Vein Occlusion (CRVO)
        2. Branch Retinal Vein Occlusion (BRVO)
        3. Anti-vascular Endothelial Growth Factor (Anti-VEGF)
        4. Corticosteroid Drugs
        5. Other Treatments
        6. Hospital Pharmacies
        7. Drug Stores & Retail Pharmacies
        8. Other End Users
      9. Singapore
        1. Central Retinal Vein Occlusion (CRVO)
        2. Branch Retinal Vein Occlusion (BRVO)
        3. Anti-vascular Endothelial Growth Factor (Anti-VEGF)
        4. Corticosteroid Drugs
        5. Other Treatments
        6. Hospital Pharmacies
        7. Drug Stores & Retail Pharmacies
        8. Other End Users
      10. Taiwan
        1. Central Retinal Vein Occlusion (CRVO)
        2. Branch Retinal Vein Occlusion (BRVO)
        3. Anti-vascular Endothelial Growth Factor (Anti-VEGF)
        4. Corticosteroid Drugs
        5. Other Treatments
        6. Hospital Pharmacies
        7. Drug Stores & Retail Pharmacies
        8. Other End Users
      11. South East Asia
        1. Central Retinal Vein Occlusion (CRVO)
        2. Branch Retinal Vein Occlusion (BRVO)
        3. Anti-vascular Endothelial Growth Factor (Anti-VEGF)
        4. Corticosteroid Drugs
        5. Other Treatments
        6. Hospital Pharmacies
        7. Drug Stores & Retail Pharmacies
        8. Other End Users
      12. Rest of Asia-Pacific
        1. Central Retinal Vein Occlusion (CRVO)
        2. Branch Retinal Vein Occlusion (BRVO)
        3. Anti-vascular Endothelial Growth Factor (Anti-VEGF)
        4. Corticosteroid Drugs
        5. Other Treatments
        6. Hospital Pharmacies
        7. Drug Stores & Retail Pharmacies
        8. Other End Users
    4. Middle East and Africa
      1. Middle East and Africa Retinal Vein Occlusion Market By Disease Type 2022-2034 (USD MILLION/ Units)
        1. Central Retinal Vein Occlusion (CRVO)
        2. Branch Retinal Vein Occlusion (BRVO)
      2. Middle East and Africa Retinal Vein Occlusion Market By Treatment 2022-2034 (USD MILLION/ Units)
        1. Anti-vascular Endothelial Growth Factor (Anti-VEGF)
        2. Corticosteroid Drugs
        3. Other Treatments
      3. Middle East and Africa Retinal Vein Occlusion Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Other End Users
      4. UAE
        1. Central Retinal Vein Occlusion (CRVO)
        2. Branch Retinal Vein Occlusion (BRVO)
        3. Anti-vascular Endothelial Growth Factor (Anti-VEGF)
        4. Corticosteroid Drugs
        5. Other Treatments
        6. Hospital Pharmacies
        7. Drug Stores & Retail Pharmacies
        8. Other End Users
      5. Turkey
        1. Central Retinal Vein Occlusion (CRVO)
        2. Branch Retinal Vein Occlusion (BRVO)
        3. Anti-vascular Endothelial Growth Factor (Anti-VEGF)
        4. Corticosteroid Drugs
        5. Other Treatments
        6. Hospital Pharmacies
        7. Drug Stores & Retail Pharmacies
        8. Other End Users
      6. Saudi Arabia
        1. Central Retinal Vein Occlusion (CRVO)
        2. Branch Retinal Vein Occlusion (BRVO)
        3. Anti-vascular Endothelial Growth Factor (Anti-VEGF)
        4. Corticosteroid Drugs
        5. Other Treatments
        6. Hospital Pharmacies
        7. Drug Stores & Retail Pharmacies
        8. Other End Users
      7. South Africa
        1. Central Retinal Vein Occlusion (CRVO)
        2. Branch Retinal Vein Occlusion (BRVO)
        3. Anti-vascular Endothelial Growth Factor (Anti-VEGF)
        4. Corticosteroid Drugs
        5. Other Treatments
        6. Hospital Pharmacies
        7. Drug Stores & Retail Pharmacies
        8. Other End Users
      8. Egypt
        1. Central Retinal Vein Occlusion (CRVO)
        2. Branch Retinal Vein Occlusion (BRVO)
        3. Anti-vascular Endothelial Growth Factor (Anti-VEGF)
        4. Corticosteroid Drugs
        5. Other Treatments
        6. Hospital Pharmacies
        7. Drug Stores & Retail Pharmacies
        8. Other End Users
      9. Nigeria
        1. Central Retinal Vein Occlusion (CRVO)
        2. Branch Retinal Vein Occlusion (BRVO)
        3. Anti-vascular Endothelial Growth Factor (Anti-VEGF)
        4. Corticosteroid Drugs
        5. Other Treatments
        6. Hospital Pharmacies
        7. Drug Stores & Retail Pharmacies
        8. Other End Users
      10. Rest of MEA
        1. Central Retinal Vein Occlusion (CRVO)
        2. Branch Retinal Vein Occlusion (BRVO)
        3. Anti-vascular Endothelial Growth Factor (Anti-VEGF)
        4. Corticosteroid Drugs
        5. Other Treatments
        6. Hospital Pharmacies
        7. Drug Stores & Retail Pharmacies
        8. Other End Users
    5. LATAM
      1. LATAM Retinal Vein Occlusion Market By Disease Type 2022-2034 (USD MILLION/ Units)
        1. Central Retinal Vein Occlusion (CRVO)
        2. Branch Retinal Vein Occlusion (BRVO)
      2. LATAM Retinal Vein Occlusion Market By Treatment 2022-2034 (USD MILLION/ Units)
        1. Anti-vascular Endothelial Growth Factor (Anti-VEGF)
        2. Corticosteroid Drugs
        3. Other Treatments
      3. LATAM Retinal Vein Occlusion Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Other End Users
      4. Brazil
        1. Central Retinal Vein Occlusion (CRVO)
        2. Branch Retinal Vein Occlusion (BRVO)
        3. Anti-vascular Endothelial Growth Factor (Anti-VEGF)
        4. Corticosteroid Drugs
        5. Other Treatments
        6. Hospital Pharmacies
        7. Drug Stores & Retail Pharmacies
        8. Other End Users
      5. Mexico
        1. Central Retinal Vein Occlusion (CRVO)
        2. Branch Retinal Vein Occlusion (BRVO)
        3. Anti-vascular Endothelial Growth Factor (Anti-VEGF)
        4. Corticosteroid Drugs
        5. Other Treatments
        6. Hospital Pharmacies
        7. Drug Stores & Retail Pharmacies
        8. Other End Users
      6. Argentina
        1. Central Retinal Vein Occlusion (CRVO)
        2. Branch Retinal Vein Occlusion (BRVO)
        3. Anti-vascular Endothelial Growth Factor (Anti-VEGF)
        4. Corticosteroid Drugs
        5. Other Treatments
        6. Hospital Pharmacies
        7. Drug Stores & Retail Pharmacies
        8. Other End Users
      7. Chile
        1. Central Retinal Vein Occlusion (CRVO)
        2. Branch Retinal Vein Occlusion (BRVO)
        3. Anti-vascular Endothelial Growth Factor (Anti-VEGF)
        4. Corticosteroid Drugs
        5. Other Treatments
        6. Hospital Pharmacies
        7. Drug Stores & Retail Pharmacies
        8. Other End Users
      8. Colombia
        1. Central Retinal Vein Occlusion (CRVO)
        2. Branch Retinal Vein Occlusion (BRVO)
        3. Anti-vascular Endothelial Growth Factor (Anti-VEGF)
        4. Corticosteroid Drugs
        5. Other Treatments
        6. Hospital Pharmacies
        7. Drug Stores & Retail Pharmacies
        8. Other End Users
      9. Rest of LATAM
        1. Central Retinal Vein Occlusion (CRVO)
        2. Branch Retinal Vein Occlusion (BRVO)
        3. Anti-vascular Endothelial Growth Factor (Anti-VEGF)
        4. Corticosteroid Drugs
        5. Other Treatments
        6. Hospital Pharmacies
        7. Drug Stores & Retail Pharmacies
        8. Other End Users
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.